Physician profile
Constance Young
NPI 1891767125
$3,650.47
in general payments reported to CMS, 2019-2025
29 companies · $717 in 2025
The $717 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $463 · 2022: $822 · 2023: $631 · 2024: $1,016 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,213.17 | 2021-2025 | |
| Novo Nordisk INC | $468.64 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $347.65 | 2023-2025 | Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $187.59 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.87 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $138.55 | 2022-2023 | Austedo Xr |
| Glaxosmithkline, LLC. | $137.92 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $119.53 | 2022-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.02 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $68.95 | 2024-2025 | |
| Lilly USA, LLC | $68.54 | 2021-2023 | Mounjaro, Trulicity, Zepbound |
| Phathom Pharmaceuticals, INC. | $65.98 | 2024-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $65.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $64.69 | 2022-2024 | |
| Pfizer INC. | $59.12 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $52.68 | 2025 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $43.79 | 2022 | |
| Nevro Corp. | $39.51 | 2022-2024 | Senza |
| Amgen INC. | $35.25 | 2024 | Otezla, Repatha |
| Lundbeck LLC | $32.89 | 2022-2024 | Rexulti |
| Exact Sciences Corporation | $32.49 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $31.70 | 2022-2023 | Auvelity |
| Amarin Pharma, INC. | $26.73 | 2021 | |
| Corcept Therapeutics | $23.11 | 2025 | Korlym |
| Tactile Systems Technology INC | $22.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.49 | 2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $16.46 | 2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $15.22 | 2021 | |
| Abbott Laboratories | $13.68 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.